Cargando…

Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms

BACKGROUND: Sleeve gastrectomy (SG) has become the primary bariatric surgery procedure in the U.S. Over 50% of people presenting for surgery have psychiatric diagnoses. The study purpose was to evaluate change in anxiety and depression symptoms and medication use after SG. METHODS: Subjects completi...

Descripción completa

Detalles Bibliográficos
Autores principales: Monte, Scott V., Russo, Kristen M., Mustafa, Esra, Caruana, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205308/
https://www.ncbi.nlm.nih.gov/pubmed/30410796
http://dx.doi.org/10.1155/2018/8532602
_version_ 1783366170346258432
author Monte, Scott V.
Russo, Kristen M.
Mustafa, Esra
Caruana, Joseph A.
author_facet Monte, Scott V.
Russo, Kristen M.
Mustafa, Esra
Caruana, Joseph A.
author_sort Monte, Scott V.
collection PubMed
description BACKGROUND: Sleeve gastrectomy (SG) has become the primary bariatric surgery procedure in the U.S. Over 50% of people presenting for surgery have psychiatric diagnoses. The study purpose was to evaluate change in anxiety and depression symptoms and medication use after SG. METHODS: Subjects completing SG with a diagnosis of anxiety and/or depression treated with medication were retrospectively identified from the electronic medical record (EMR) of Synergy Bariatrics, a department of the Erie County Medical Center. Phone outreach was made to complete seven-point global impression of change scale classifying symptom improvement or worsening in the 3- to 6-month postoperative period. Improvement or worsening was defined as either all reported symptoms improving or worsening or ≥1 improving or worsening while remaining unchanged. If ≥1 symptom improved and worsened, it was classified as mixed. No change required the same profile before and after surgery. Medication, dose, and changes were identified by EMR, verified during interview and classified as no change, discontinued, decreased, or increased. RESULTS: 59 subjects completed the interview. 21 subjects were diagnosed with anxiety. 13 (62%) had no change in therapy and 5 (24%) decreased. Symptoms improved in 12 (57%), worsened in 3 (14%), and mixed in 5 (24%). When symptoms improved, the same dose was present in 7/12 (58%) and dose decreased in 3 (25%). 51 subjects were diagnosed with depression. 32 (63%) had no change in therapy, 11 (21%) discontinued, and 4 (8%) decreased. Symptoms improved in 34 (67%), mixed in 10 (20%), worsened in 4 (8%), and unchanged in 3 (6%). When symptoms improved, the same regimen and dose was present in 21/34 cases (62%) and discontinued in 9 (26%). CONCLUSION: Anxiety symptoms improved in >50% of subjects at predominantly the same or reduced dosage. Depression symptoms improved in 67% and commonly without therapy change. These data suggest evidence that patients undergoing SG while on medication for anxiety or depression may have early symptom improvement on the same or lessened dosage.
format Online
Article
Text
id pubmed-6205308
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62053082018-11-08 Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms Monte, Scott V. Russo, Kristen M. Mustafa, Esra Caruana, Joseph A. J Obes Research Article BACKGROUND: Sleeve gastrectomy (SG) has become the primary bariatric surgery procedure in the U.S. Over 50% of people presenting for surgery have psychiatric diagnoses. The study purpose was to evaluate change in anxiety and depression symptoms and medication use after SG. METHODS: Subjects completing SG with a diagnosis of anxiety and/or depression treated with medication were retrospectively identified from the electronic medical record (EMR) of Synergy Bariatrics, a department of the Erie County Medical Center. Phone outreach was made to complete seven-point global impression of change scale classifying symptom improvement or worsening in the 3- to 6-month postoperative period. Improvement or worsening was defined as either all reported symptoms improving or worsening or ≥1 improving or worsening while remaining unchanged. If ≥1 symptom improved and worsened, it was classified as mixed. No change required the same profile before and after surgery. Medication, dose, and changes were identified by EMR, verified during interview and classified as no change, discontinued, decreased, or increased. RESULTS: 59 subjects completed the interview. 21 subjects were diagnosed with anxiety. 13 (62%) had no change in therapy and 5 (24%) decreased. Symptoms improved in 12 (57%), worsened in 3 (14%), and mixed in 5 (24%). When symptoms improved, the same dose was present in 7/12 (58%) and dose decreased in 3 (25%). 51 subjects were diagnosed with depression. 32 (63%) had no change in therapy, 11 (21%) discontinued, and 4 (8%) decreased. Symptoms improved in 34 (67%), mixed in 10 (20%), worsened in 4 (8%), and unchanged in 3 (6%). When symptoms improved, the same regimen and dose was present in 21/34 cases (62%) and discontinued in 9 (26%). CONCLUSION: Anxiety symptoms improved in >50% of subjects at predominantly the same or reduced dosage. Depression symptoms improved in 67% and commonly without therapy change. These data suggest evidence that patients undergoing SG while on medication for anxiety or depression may have early symptom improvement on the same or lessened dosage. Hindawi 2018-10-15 /pmc/articles/PMC6205308/ /pubmed/30410796 http://dx.doi.org/10.1155/2018/8532602 Text en Copyright © 2018 Scott V. Monte et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Monte, Scott V.
Russo, Kristen M.
Mustafa, Esra
Caruana, Joseph A.
Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title_full Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title_fullStr Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title_full_unstemmed Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title_short Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
title_sort impact of sleeve gastrectomy on psychiatric medication use and symptoms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205308/
https://www.ncbi.nlm.nih.gov/pubmed/30410796
http://dx.doi.org/10.1155/2018/8532602
work_keys_str_mv AT montescottv impactofsleevegastrectomyonpsychiatricmedicationuseandsymptoms
AT russokristenm impactofsleevegastrectomyonpsychiatricmedicationuseandsymptoms
AT mustafaesra impactofsleevegastrectomyonpsychiatricmedicationuseandsymptoms
AT caruanajosepha impactofsleevegastrectomyonpsychiatricmedicationuseandsymptoms